Last Price
1.78
Today's Change
+0.255 (16.72%)
Day's Change
1.71 - 1.83
Trading Volume
15,599,748
Market Cap
2 Billion
Shares Outstanding
1 Billion
Avg Volume
4,236,626
Avg Price (50 Days)
1.24
Avg Price (200 Days)
0.95
PE Ratio
-11.12
EPS
-0.16
Earnings Announcement
20-Feb-2025
Previous Close
1.52
Open
1.74
Day's Range
1.71 - 1.83
Year Range
0.255 - 1.83
Trading Volume
15,599,748
1 Day Change
16.72%
5 Day Change
31.85%
1 Month Change
23.61%
3 Month Change
79.80%
6 Month Change
66.36%
Ytd Change
483.61%
1 Year Change
421.49%
3 Year Change
-1.11%
5 Year Change
5.33%
10 Year Change
-52.53%
Max Change
187.33%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.